Teladoc Health (TDOC) President Kelly Bliss Sells $21K of Stock
Kelly Bliss, President of U.S. Group Health at Teladoc, sold 2,500 shares valued at $21,250.
Reviewed by automated data checks against the source filing. How we make and check alerts
Kelly Bliss, President, U.S. Group Health at Teladoc Health, Inc. ($TDOC), sold 2,500 shares at an average price of $8.50, worth about $21,250, on June 29, 2026. The trade was reported to the SEC in a Form 4 filing and was made under a pre-arranged Rule 10b5-1 trading plan.
Since the trade, $TDOC is up 6.9% after 1 week, up 5.6% after 1 month and down 34.8% to date (from the $8.69 close on Jun 29, 2026).
TDOC
Teladoc Health, Inc.
Key Points
- On June 29, 2026, Kelly Bliss sold 2,500 shares of Teladoc Health, Inc. for about $21,250.
- The stock closed at $8.56 on the day of the sale, down from a previous close of $6.30.
- Kelly Bliss's planned sale is part of ongoing insider activity as the stock remains under pressure in the healthcare sector.
Get $TDOC trade alerts by text
We text you when insiders, Congress or big funds trade $TDOC. Free.
Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Teladoc Health, Inc. alert may contain errors. Disclosures
Insider Buying and Selling at Teladoc Health, Inc.
Kelly Bliss, who serves as President of U.S. Group Health at Teladoc Health, Inc. (NYSE: TDOC), sold 2,500 shares on June 29, 2026. The transaction was valued at approximately $21,250, given the sale price of $8.50 per share. This planned sale reflects Bliss's strategy rather than a sudden change in confidence.
Market Context for the Stock
Teladoc is currently trading at $8.56, which is a notable point considering its previous close of $6.30. The stock has seen a range between $4.40 and $9.89 over the past year. This positions it closer to its 52-week high but still shows the volatility often seen in the healthcare sector.
Analysts Set New Price Targets
Several analysts are keeping a close eye on Teladoc. On August 3, 2026, Citigroup maintained a "Neutral" rating with a price target of $7.50, down from $11.00. Canaccord Genuity also kept a "Buy" rating while adjusting its target from $11.00 to $10.00 on July 30, 2026. Meanwhile, Evercore ISI Group downgraded its target to $7.50, reflecting concerns about the company's revenue growth and overall performance.
What Teladoc Health, Inc. Does
Teladoc Health, Inc. provides virtual healthcare services globally, operating through segments like Integrated Care and BetterHelp. The company continues to adapt its business model to the evolving healthcare landscape, which is crucial for its future performance.
What's Ahead for Teladoc Health, Inc.
Investors will be attentive to upcoming developments, including Teladoc's next earnings report scheduled for October 28, 2026. As with all insider trades, this sale by Kelly Bliss is part of a planned transaction, and investors should consider it in the broader context of Teladoc's performance in the healthcare market.
Related Filing Alerts
Source: Kelly Bliss's Form 4 filing on $TDOC (Jun 29, 2026). Find the original filing: TDOC Form 4 filings on SEC EDGAR. Written by software, not financial advice. How we make alerts